Alterations to the middle cerebral artery of the hypertensive-arthritic rat model potentiates intracerebral hemorrhage

Amy Randell¹, Killol Chokshi¹, Brittany Kane¹, Hilary Chang¹, Safaa Naïel², Jeffrey G. Dickhout² and Noriko Daneshtalab¹

¹ School of Pharmacy, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Canada
² Department of Medicine, Division of Nephrology, McMaster University, Hamilton, Ontario, Canada

ABSTRACT

Aims: We have recently created an age-dependent hypertensive-mono-arthritic animal model from the stroke-resistant spontaneously hypertensive rat to model populations with autoimmune disease who are hypertensive and are prone to stroke. The model exhibits signs of hemorrhagic stroke (HS) subsequent to chronic inflammation and hypertension. HS is also associated with the inability of middle cerebral arteries to undergo pressure dependent constriction (PDC). We investigated alterations in the cerebrovasculature of our hypertensive mono-arthritic animals that develop stroke.

Main Methods: Animals were fed either a high salt diet (HSD) (4% NaCl) or Purina chow (0.58% NaCl) from weaning. Complete Freund's Adjuvant (CFA) was injected into the left hind paw at 21–28 weeks; controls received saline and histological and functional studies were performed.

Results: Brain damage was more prominent with the high salt, with inflammation exacerbating the damage. High salt alone significantly decreased middle cerebral artery's (MCA's) ability to undergo PDC. Inflammation significantly decreased the ability of cerebrovasculature to respond to pressure step in the regular salt diet. The responses to vasoactive peptides were also significantly attenuated in both inflamed groups regardless of diet.

Conclusion: Induction of chronic systemic inflammation increases brain damage, and affect the MCA's vasogenic function, decreasing its ability to respond to intraluminal pressure. HSD further exacerbates organ damage associated with chronic inflammation, further compromising cerebrovascular function, and likely increasing the incidence of intracerebral hemorrhage and injury.

INTRODUCTION

Autoimmune diseases such as rheumatoid arthritis (RA) are a chronically progressive inflammatory disease, with the leading cause of death being due to cardiovascular (CV)
complications rather than the arthritis itself (Solomon et al., 2003; Gonzalez et al., 2008). Fundamental studies indicate significant risk of stroke in autoimmune arthritis, with patients with RA having a 30% increase in stroke over age-matched controls (Lindhardsen et al., 2012; Zöller et al., 2012). The risk of death from the first incidence of stroke has also been shown to be significantly higher for RA patients compared to non-arthritic subjects (Solomon et al., 2003; Book, Saxne & Jacobsson, 2005; Sokka, Abelson & Pincus, 2008). Of all stroke subtypes, hemorrhagic stroke (HS) has the highest mortality rate, approaching 50% within the first month (Thrift et al., 1996; Donnan et al., 2008), and is characterized by cerebral blood flow alteration.

Cerebral blood flow autoregulation is governed by a variety of physical cues (including sheer stress, pressure, hypoxia) and endogenous chemical stimuli (such as peptides, and cytokines) (Bassenge & Heusch, 1990; Vanhoutte & Mombouli, 1996). Pressure dependent constriction (PDC) in middle cerebral artery (MCA) ensures adequate and controlled perfusion of the small arteries feeding the brain (Johnson, 1986). Studies in stroke-prone spontaneously hypertensive rats (SHRsp) have revealed that MCAs ability to undergo pressure induced constriction is lost after HS (Smeda, 1992). The MCAs from post-stroke SHRsp have also lost the ability to respond to endothelial-mediated responses to various peptides such as bradykinin and nitric oxide synthase (NOS) inhibitors. Responses to vascular smooth muscle-mediated protein kinase C (PKC) activation (with phorbol dibutyrate) and intracellular calcium release (with vasopressin) are also attenuated (Smeda & King, 2000; Danesh talab & Smeda, 2010). Although chronic hypertension and chronic inflammation have both been individually correlated to vascular dysfunction (Bassenge & Heusch, 1990; Sutherland & Auer, 2006; Sprague & Khalil, 2009), the impact of these factors in conjunction with the effectiveness and efficiency of MCA function has not yet been investigated.

We have recently established a model of aged spontaneously hypertensive rats (SHR) that are originally stroke-resistant, but which, upon induction of adjuvant-induced arthritis, develop severe signs of intracerebral hemorrhage. We also tested the effect of 4% NaCl on hemorrhage development and observed that high salt diet (HSD) increases intracerebral hemorrhage severity (Randell & Danesh talab, 2016). The present study is designed to describe the impact of chronic inflammation, concurrent hypertension, and HSD on the ability of the MCA to respond to intraluminal pressure and to vasoactive peptides, and investigate its impact on degree cerebral damage. We believe the physiological conditions manifested by this animal model will help illuminate the mechanisms of cerebrovascular function of patients suffering from both RA and hypertension and lead to better understanding for treatment options to minimize fatal stroke.

**MATERIALS AND METHODS**

**Animals**

All experimental procedures and animal breeding was carried out at Memorial University of Newfoundland Animal Care Facility and were in compliance with guidelines and recommendations set forth by the Animal Care ethics committee (Protocol #15-30-ND) and the Canadian Council on Animal Care (Guide to Care and Use of Experimental
Animals, vol. 1, 2nd ed.). In total, 45 male Stroke resistant SHE (Original stock from Charles River Laboratories, Quebec, Canada) were included in the study. The animals were bred in-house and were housed two per cage in ventilated cages under standard light cycle (12 h light/dark), controlled temperature, and humidity conditions. Experimental design was implemented at 21–28 weeks of age. Ad libitum access to food and water was permitted.

Experimental design
SHR-high salt diet (SHR-HSD) groups were fed a Japanese-style HSD containing 4% NaCl (Zeigler Bros, Gardners, PA, USA) from weaning. SHR-regular diet (SHR-RD) groups were maintained on standard rat chow (Laboratory Rodent Diet 500I; Lab Diet, St. Louis, MO, USA; 0.58% NaCl). At 21–28 weeks of age, they were randomly divided into four groups based on diet (HSD or RD) and treatment (Complete Freund’s Adjuvant (CFA) model of mono-arthritis or Saline (SAL) injected control). They were labelled SHR-HSD-SAL (n = 10), SHR-HSD-CFA (n = 14); SHR-RD-SAL (n = 11), SHR-RD-CFA (n = 10). Procedures for arthritis induction, weekly monitoring, and results are all described and published earlier (Randell & Daneshtalab, 2016). Briefly, the animals were anesthetized (isoflurane; Sigma), and either CFA (0.07 ml of 700 mg M. butyricum) or sterile 0.9% saline solution (0.07 ml) was injected (intradermal) into the plantar surface of the left hind paw of 21–28 week old SHRs at day 0 of the experimental procedure and animals were maintained for 21 days.

Sample isolation and tissue processing
Necropsy was performed on day 21 after deep anesthesia (50/10 mg/kg of Ketamine: Xylazine) and exsanguination. The brain was removed and placed in oxygenated ice-cooled (≈3 °C) HEPES Bicarbonate Buffer (pH 7.4). The right and left MCAs were isolated, starting at the point distal to where it crosses the rhinalis fissure and mounted on a pressure myograph. The rest of the brain were immediately fixed in a 10% Neutral Buffered Formalin (Thermo Fisher) for further processing.

Tissue preparation for histological assessment and immunofluorescent analysis
Upon fixation, samples were embedded in paraffin, and 6 μm cryosections were cut. Samples were stained using hemotoxylin and eosin (H&E) by standard procedures. Brain sections were also stained for astrocytes and microglia/macrophages in the cortex using glial fibrillary acidic protein (GFAP)-Cy3 (1:1,000; Sigma Aldrich, Montreal, CAN) and ionized calcium binding adaptor molecule 1(Iba-1; 1:1,000, Wako Chemicals, Richmond, VA, USA). Secondary antibody of Cy2 Goat Anti-rabbit (1:200; Jackson Immunoresearch, West Grove, PA, USA) and 4',6-diamidino-2-phenylindole (DAPI) (1:1,000; Invitrogen, Hamilton, ON, USA) were applied in the second day according to established protocol. Stacks of images with 1 μm increments in a total of six slices in depth were collected with a confocal microscope (FV500; Olympus) with FluoView (Olympus) software.
Quantification of neural damage

Neural and brain damage associated with the treatments were analyzed using the H&E stains of the samples, and scored using a scheme based on combinative semi-quantitative scoring system as outlined in recent research (Fedchenko & Reifenrath, 2014). To maximize detection and repeatability of the scoring system, our scoring contains four score levels (Shackelford et al., 2002). Table 1 outlines the grading scheme associated with each parameter scored. Cell vacuolation and neuron degeneration determine axonal swelling and associated cell death in the white matter, which occurs spontaneously or via a wide range of stimuli (Henics & Wheatley, 1999). The grading scheme for this cell death are valued points from 0 to 10, where cell count is graded in point system. The vacuolation is graded in factor of 10 cells per point, with the maximum number of vacuolation quantifiable being 80. The degenerating neurons were graded in factor of two cells per point, and the grading system from 0–10 was sufficient as the maximum number of degenerating neuron quantifiable was eight. Areas of edema and areas of cell infiltration (also indicators of brain injury and damage) were quantified separately, and graded in a factor of 10% for each point, the total being the complete image area. The grading scheme for the areas is a modified version adopted from the “quickscore” system (Detre, Saclani Jotti & Dowsset, 1995), which assigns values from 1 to 6 in proportion and multiplication is recommended instead of addition for processing of final score range. A total final score was determined via summation of the four separate parameters to indicate total damage evident in the samples.

Quantification of Iba-1 and GFAP staining

Confocal images were analyzed with ImageJ software (National Institutes of Health, ImageJ1.40) and FIJI plugin. The images stained for astrocytes (GFAP), microglia (Iba-1) & nucleus (DAPI) were calibrated and gray scaled. Mean integrated density, area of measurement, background integrated density was measured for astrocytes. We used Corrected total tissue fluorescence (CTTF), where CTTF = \{(MID) \times (TA)\} – BMID; MID is the mean integrated density, TA is the total area of measurement, BMID is the background mean integrated density, with the unit being pixels per μm. Triplicate reading of background intensity per image were obtained and the mean was used for final calculation.

The quantification of microglia was based on cell count and type of microglia. Microglia undergo transformation with injury and are activated. They adopt amoeboid shape with very short projections. The amoeboid shaped cells that were counted as activated microglia. The microglia which did not undergo transformation were labelled as type 2 cells. The total detectable microglia cells over DAPI Stained nuclei was used for the final analysis.

Pressure myograph experiments

All chemicals used in the pressure myograph experiments were purchased from Sigma Aldrich (Montreal, CAN) unless otherwise stated.

Isolated MCAs were mounted onto the Single Vessel Chamber component of the Pressure Servo System (Living Systems Instrumentation, St Albans City, VT, USA) for
pressure myograph studies. Vascular response was imaged using an inverted microscope and measured using a Video Dimension Analyzer (Living Systems Instrumentation, VT, USA). Mounted vessels were tied off creating a blind sack and pressurized to 100 mmHg and equilibrated for 30–45 min in an oxygenated (95:5% O₂:CO₂) HEPES bicarbonate buffer (NaCl, 130 mM; KCl, 4 mM; MgSO₄, 1.2 mM; NaHCO₃, 4 mM; CaCl₂, 1.8 mM; HEPES 9.9 mM; KH₂PO₄, 1 mM; EDTA, 2.4 M; Glucose, 5.8 mM) in a temperature controlled (37 °C) environment. Baumbach & Heistad (1989) previously described a decrease in blood pressure (BP) of > 50% between that measured in the femoral or carotid artery compared to that measured in the distal portions of the middle cerebral vessels (Baumbach & Hajdu, 1993; Baumbach, Faraci & Heistad, 1994). As a result, all their pressure myograph experiments were conducted at a resting pressure of 100 mmHg. We also conducted our myograph experiments in the MCA at resting pressure of 100 mmHg, as we believe the setting accurately models physiological mean BP in vivo in the MCA of the SHR, as arterial systolic BP ranges from 200 to 230 mmHg (Yamori, 1984).

PDC was evaluated first. Following equilibration, the pressure was decreased to 0 mmHg for 6 min to disengage PDC (Smeda & King, 2000). After this resting period, the pressure was immediately reapplied to 100 mmHg and lumen diameter was recorded (at the instant when the vessel experienced maximal pressure-mediated dilation; t = 0). The ability of the artery to constrict to pressure was determined in the change in MCA lumen diameter between 1 s to 6 min after the reapplication of pressure. The percentage decrease in lumen diameter observed in response to the latter pressure step in the MCAs was calculated to be PDC. The bradykinin (1.6 μM) mediated response was tested by measuring the maximal vasodilatory response between 15 s to 2 min, and were assessed at 100 mmHg pressure. Results were expressed as a percentage of maximal

### Table 1 Scoring scheme for quantifying brain damage

| Score assigned | Number of cells undergoing vacuolation (A) | Number of degenerating neurons (B) | Percentage of area of oedema (C) (%) | Percentage of area of cell infiltration (D) (%) |
|----------------|-------------------------------------------|-----------------------------------|-------------------------------------|-----------------------------------------------|
| 0              | 0                                         | 0                                 | 0                                   | 0                                             |
| 1              | 1–10                                      | 1–2                               | 1–10                                | 1–10                                          |
| 2              | 11–20                                     | 3–4                               | 11–20                               | 11–20                                         |
| 3              | 21–30                                     | 5–6                               | 21–30                               | 21–30                                         |
| 4              | 31–40                                     | 7–8                               | 31–40                               | 31–40                                         |
| 5              | 41–50                                     | 9–10                               | 41–50                               | 41–50                                         |
| 6              | 51–60                                     | 11–12                             | 51–60                               | 51–60                                         |
| 7              | 61–70                                     | 13–14                             | 61–70                               | 61–70                                         |
| 8              | 71–80                                     | 15–16                             | 71–80                               | 71–80                                         |
| 9              | 81–90                                     | 17–18                             | 81–90                               | 81–90                                         |
| 10             | 91–100                                    | 19–20                             | 91–100                              | 91–100                                        |
relaxation produced by nifedipine (3 μM). Maximal responses observed within 15 s, were followed by reconstriction to a Lumen Diameter (LD) comparable to that present prior to the application of the peptide.

After the preparation was flushed with ~25 ml of fresh HEPES bicarbonate buffer, the effect of NOS inhibition was then tested (L-NAME (100 μM)). Lumen diameter was recorded immediately and at 5 min and the percent constriction was determined from prior to L-NAME application. After another flush with HEPES buffer, the MCAs were maximally dilated at 100 mmHg with nifedipine (3 μM). Under this condition, the constriction in response to intracellular Ca\(^{2+}\) release from the sarcoplasmic reticulum was measured by addition of 1.23 × 10\(^{-7}\) M vasopressin. There is a phasic response associated with vasopressin under these conditions, which does not occur under conditions where sarcoplasmic calcium store is depleted with cyclopiazonic acid (10 μM), or calcium free 5 mM ethylene glycol-bis(\(\beta\)-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA) Krebs. The sarcoplasmic calcium store with the MCA smooth muscle is only replenished by calcium entry through the L-type channels, which, upon blocking, demonstrates the phasic MCA contractile response corresponding to release and depletion of the sarcoplasmic calcium stores. This phasic response was recorded within the 2 min of vasopressin application. PKC activation was determined by addition of 1 μM phorbol-dibutyrate, with maximal contraction measured after 5 min of incubation. As with vasopressin, the MCAs first underwent maximal dilation at 100 mmHg using nifedipine (3 μM). Under the latter condition, phorbol dibutyrate constriction is PKC mediated and completely inhibited by PKC inhibitors chelerythrine (12 μM) or bisindolylmaleimide (5 μM). The percent contraction from this maximally dilated state after nifedipine treatment was calculated after the use of phorbol dibutyrate.

Statistical analysis
Statistical analysis was performed using SigmaPlot 12.5 (Systat Software Inc., San Jose, CA, USA) and Excel 2010 (Microsoft Corporation, Redmond, WA, USA). Data were analyzed using either one-way, or two-way ANOVA, and Holm-Sidak post-hoc analysis. Values of p < 0.05 were considered statistically significant. Except where otherwise indicated, all data are expressed as mean ± SEM.

RESULTS
Effect of diet and systemic inflammation
Neuronal and brain damage
H&E stains of the brains from the four experimental groups were imaged to determine degrees of intracerebral and neural damage particularly around the middle cerebral area (Figs. 1A–1D). Cell vacuolation, neuron degeneration, areas of edema, and cell infiltration appeared to increase with CFA treatment, regardless of diet. Animals on a high salt diet alone (HSD SAL) also appeared to exhibit a similar degree of neuronal damage as CFA treatment. The degree of neuronal damage was further evaluated using a four parameter semi-quantifiable scoring system (Fig. 2). Total brain damage scoring indicated
Figure 1  Brain pathology using H&E stains. Representative images of H&E stains of brain slices (6 µm) imaged at 10x and 20x objectives for regular diet SHRs with SAL and CFA treatments (RD SAL; A, RD CFA; B) and high salt diet SHRs with SAL and CFA treatment (HSD SAL; C, HSD CFA; D). Areas of neural cell vacuolation (circle), neural degeneration (short arrow), area of oedema (open triangle), and cell infiltration of inflammatory origin (long arrow) are indicated between treatment groups (A–D).
a significant difference in degree of damage with induction of systemic inflammation, as well as with the HSD, compared to RD SAL control. Interestingly, out of the four parameters of brain damage, the most indicative sign of neural damage appeared to be presence of cell vacuolations (Table S1).

**Signs of inflammatory activation: central and systemic**

Total microglia and astrocytes were imaged using brain slices immunostained with Iba-1 and GFAP (Fig. 3). Semi-quantitative analysis of the number of activated microglia indicated a trend toward increase in activation of microglia with CFA treatment; a statistically significant increase in its activation was observed in the HSD CFA compared to the RD SAL group (Fig. 4A). Quantification of the integrated density of GFAP staining determined astrocyte spread from the cerebral neocortex towards the corpus callosum. A numerical trend toward an increase in integrated density in the RD-CFA compared to RD SAL was also observed (Fig. 4B). HSD appeared to increase both astrocyte density and its spread from the neocortex, as well as the expression of activated microglia. However, no statistical significance was observed. CFA treatment in the HSD-CFAs caused a significant increase in astrocyte density compared to RD SAL, indicating an increase in neuro-inflammatory reaction, likely associated with CFA injection and HSD combined. The resulting increase in neuro-inflammation may contribute to the degree
Figure 3  **Immunostaining for astrocytes and microglia.** Representative immunostaining of the cortex of the brain slices (6 μm) stained for astrocytes (GFAP- 1:1,000), microglia (Iba-1- 1:1,000) and DAPI (1:1,000) is used for nuclear staining. Staining was performed in brains of regular diet SHRs with SAL and CFA treatment (RD SAL; A, RD CFA; B) and high salt diet SHRs with SAL and CFA treatment (HSD SAL; C, HSD CFA; D). Images are at 20× objective, and scale at 100 μm for Immunofluorescence. Images were later semi-quantified for activated microglia using changes in microglia morphology (E I: Activated microglia) and area of astrocyte projection fluorescence (E II: Astrocyte spread). Triangles represent normal microglia morphology, and the arrow is the ameboid microglia which are activated. Shortened projections and bright nucleus were deemed to be microglia on the verge of full activation. Oval represent the degree of astrocyte spread from the peripheral cortex moving into the corpus colusum. Images of the DAPI staining merged with the Iba-1 stain and GFAP stain are also represented.
of severity of damage in the brain with CFA treatment, exacerbated by HSD, as previously quantified in this animal model. An example of the hemorrhages observed with CFA treatment is shown in Fig. S1. In order to determine whether we also observed other organ damage associated with the chronic inflammation, we analyzed the kidneys for presence of proteinaceous casts and inflammatory infiltrate related to both diet and inflammatory injury (Fig. S2). We found RD SAL have normal glomeruli, with little to no proteinaceous casts within the cortex and medulla. In comparison, the RD CFA have

**Figure 4** Semi-quantification of activated microglia and astrocytes in the brain. The number of activated microglia (Iba-1 staining; A) and astrocyte projection fluorescence (GFAP staining; B) in brains of regular diet SHRs with SAL and CFA treatment (RD SAL; RD CFA) and high salt diet SHRs with SAL and CFA treatment (HSD SAL; HSD CFA) were analyzed and quantified. Activated microglia was morphologically determined to be amoeboid shaped with short projections from the fluorescence images and the total detectable microglia cells overlapped with the DAPI Stained nuclei were used for the quantification analysis over a 630 μm area. The integrated density of astrocytes, presented as CTTF (Corrected total tissue fluorescence), was measured for the same area. The sample sizes ranged from n = 3–6/group. All values represent mean ± SEM. Data was analyzed using one-way ANOVA using the Holm-Sidak post-hoc test. * p < 0.05, and ** p < 0.001.
occasional proteinaceous casts in the medulla, as do the HSD SAL group. Interestingly, the HSD SALs also express minimal inflammatory infiltrate and occasional obsolete glomerulus. In contrast, the HSD CFA express abundant protein casts, abundant obsolete glomeruli, severe glomerular sclerosis, and prominent inflammatory infiltrate around the glomeruli and blood vessels.

**Effect of diet and inflammation on vascular function in the MCA**

*Pressure dependent constriction*

Both diet and CFA treatment affected PDC (Fig. 5A). CFA treatment appeared to significantly diminish the ability of MCAs to constrict to pressure in the RD group compared to SAL controls. However, there was no significant difference in MCA vasoconstriction in HSD CFA compared to HSD SAL, indicating that HSD alone had greatly diminished the vessel’s ability to respond to luminal pressure. This is further evidenced by a significant decrease in PDC response in the HSD SAL group compared to the RD SAL group ($p = 0.01$).

*Endothelial function: response to bradykinin*

Figure 5B depicts the endothelial vasodilatory response of MCAs to addition of bradykinin (1.6 $\mu$M). The effect of CFA was not evident within MCAs of RD groups (RD CFA vs. RD SAL). However, a statistically significant decrease in response was observed in the MCAs from HSD-fed CFA rats compared to HSD SAL rats ($p = 0.015$). There was no difference in vessel response to bradykinin due to the HSD (i.e. RD SAL vs. HSD SAL). However, comparison between inflamed groups of the different diets indicated a significant decrease in relaxation in the HSD CFA cohort compared to the RD CFA ($p = 0.006$), demonstrating the combined effect of both HSD and inflammation on bradykinin response in the MCAs.

*Endothelial function: NOS function*

Endothelial-mediated relaxation by nitric oxide (NO) was tested by the addition of a non-specific NOS inhibitor L-NAME (100 $\mu$M), eliminating NO-mediated vasodilation (Fig. 5C). Induction of inflammation via CFA did not significantly decrease response to L-NAME in the RD groups despite a trend in depressed response (RD CFA vs. RD SAL). However, there was a statistically significant decrease observed with CFA treatment in the HSD groups (HSD CFA vs. HSD SAL; $p = 0.018$). No statistically significant difference was noted in MCA response to L-NAME between diets (RD-SAL vs. HSD-SAL).

*Intracellular calcium response*

Intracellular Ca$^{2+}$ release was evaluated in the presence of nifedipine (L-type calcium channel blocker; 3 $\mu$M) and analyzing the MCAs response to intracellular Ca$^{2+}$ release by vasopressin (1.23 $\times$ $10^{-7}$M). There was no significant difference in the treatments in the RD group in their response to sarcoplasmic calcium release (RD CFA vs. RD SAL). However, in the HSD group, a statistically significant difference was observed between inflamed and non-inflamed rats, as the MCAs of HSD CFA group had a significant diminished response to vasopressin compared to the HSD SAL group ($p = 0.03$) (Fig. 5D).
Figure 5 Effect of complete Freund’s Adjuvant and/or high salt diet on middle cerebral artery function. Pressure myograph studies were performed in the MCAs isolated from RD SAL (n = 9–12), RD CFA (n = 10–13), HSD SAL (n = 11–13), HSD CFA (n = 9–16). The ability to respond to pressure step (PDC; A) showed RD SAL maintained normal PDC response. There was a significant decrease in PDC in RD CFA vs. RD SAL. No difference was observed between HSD CFA vs. HSD SAL. HSD itself significantly diminished capacity for MCA’s ability to undergo PDC HSD SAL vs. RD SAL. Bradykinin response (B) show no difference in bradykinin-induced vasodilation between RD CFA vs. RD SAL. However, endothelial vasodilatory response was significantly diminished in HSD CFA vs. HSD SAL. There was no significant difference between HSD SAL vs. RD SAL. L-NAME response (C) indicate a trend toward diminished L-NAME response is seen in RD CFA vs. RD SAL, but it was not significant. The HSD CFA response to L-NAME was, however, significantly lower than that of HSD SAL. HSD did not affect L-NAME response vs. RD (HSD SAL vs. RD SAL). Constriction response to Vasopressin (D) show no significant difference between RD CFA vs. RD SAL. However, inflammation induced a significant decrease in response to vasopressin in HSD CFA vs. HSD SAL. No difference was observed to vasopressin due to diet (HSD SAL vs. RD SAL). Response to phorbol dibutyrate (E), indicate induction of inflammation significantly diminishes response to PKC activation regardless of diet (RD CFA vs. RD SAL and HSD CFA vs. HSD SAL). There were no diet-induced differences in response to phorbol dibutyrate. All values represent mean ± SEM. Data was analyzed using two-way ANOVA using the Holm-Sidak post-hoc test. * p < 0.05.
There was no difference in vessel contraction in response to vasopressin between diets (RD SAL vs. HSD SAL).

**PKC activation**
Phorbol Dibutyrate (1 μM) was added to the MCAs to evaluate vascular smooth muscle response to PKC activation in the presence of nifedipine (3 μM) (Fig. 5F). A significant difference was observed in the inflamed (CFA) groups compared to SAL in both RD and HSD groups (p = 0.047, RD CFA vs. RD SAL; p = 0.018, HSD CFA vs. HSD SAL). There was no statistical difference in response to PKC activation between the diets (RD SAL vs. HSD SAL).

**DISCUSSION**
The arthritic hypertensive model exemplifies a moderate arthritic response localized in one paw, which induces systemic inflammation and also maintains high systolic blood pressure independent of diet or inflammatory treatment as previously published by our group (Randell & Daneshtalab, 2016). The joint damage with our mono-arthritis model is reminiscent of the changes that occur with RA (Kannan, Ortmann & Kimpel, 2005) with increases in systemic inflammatory mediator Tumor Necrosis Factor alpha (TNF-α) (Randell & Daneshtalab, 2016). Uniquely, we had also found an associated incidence of HS alongside increase in systemic inflammatory injury. In this study, we have determined there is loss of the ability of the MCA to undergo PDC and respond to vasogenic drugs, which likely contribute to incidence of intracerebral hemorrhage in this model. These differences are either dependent on chronic inflammation (CFA injection), diet (HSD or RD) or both.

We have previously shown that there is an increase in systemic TNF-α in the HSD-CFA groups (Randell & Daneshtalab, 2016). TNF-α directly affects joint degeneration and destruction in arthritis (Saklatvala, 1986), and induces a cascade of other pro-inflammatory cytokines and proteins such as interleukins, prostaglandins, and angiotensin II in peripheral organs (Brennan & Feldmann, 1992; Feldmann & Maini, 2008). H&E staining within the cortex of the brain show evidence of an increase in axonal and nerve cell damage indicated by neural vacuolation, nerve degeneration, edema, and cell infiltrates with CFA treatment (Figs. 1 and 2). Astrocyte branching within the brain also appear to increase, spreading inward from the cortex into the grey matter with inflammatory stimulus. Central inflammation is also apparent with increases in activated microglia associated with the systemic inflammatory injury (Figs. 3 and 4). Our observations lead us to believe the central inflammatory response and neuronal damage is associated with the increase in pro-inflammatory levels with systemic inflammation. The pro-inflammatory mediators may also increase the nephro-glomerular damage in the kidneys (also observed in our animal model) which in turn increase urea and uric acid, weakening the blood brain barrier (BBB) and increasing toxicity and neural inflammatory response (Henke et al., 2007; Izawa-Ishizawa et al., 2012).

HSD itself appears to cause neural inflammation, damage, and increased immune activation in both kidneys and the brain; (Figs. 1–4 and S2). Slices of brain cortex indicate...
HSD-driven increases in astrocytes branching and expression, as well as numerical increases in activated microglia staining (Fig. 4). The role of sodium driving autoimmune diseases has been presented by various groups in the last couple of years, with sodium chloride activating inflammatory pathways (Croxford, Waisman & Becher, 2013; Kleinewietfeld et al., 2013). Our model clearly indicates that the addition of inflammatory insult to the HSD exacerbates the inflammatory response, and likely increases the severity of the cerebral hemorrhage that had been observed in the HSD CFA rats.

When we examine the MCA's ability to undergo PDC, we find that the loss of MCA function is linked to spontaneous HS development in the SHRsps model. We have previously shown loss of MCA function in the SHRsps contributed to the inability to undergo PDC and autoregulation in the brain (Smeda & Daneshtalab, 2011). The loss of response to intraluminal pressure in the HSD SAL rats is likely attributed to the effects of both inflammation and chronic HSD on the endothelium. Endothelial dysfunction secondary to chronic salt intake has been linked to increased endothelial production of factors that increase the production of reactive oxygen species (ROS) (Durand et al., 2010; Feng et al., 2015). Significantly diminished MCA function due to the high salt may have decreased the endothelial function such that inflammatory insult via CFA was negligible in the HSD CFA group. The direct effect of inflammatory insult on MCA function is observed in our RD CFA groups, as the MCAs did not contract significantly to high luminal pressure. Both the endothelium and vascular smooth muscle cell dysfunction may have occurred due to the trigger of physical and chemical stress signals (Numata, Takahashi & Inoue, 2015) and kinases such as NF-κB (Chauhan et al., 2014). The trigger may affect specific endothelial transient receptor potential (TRP) channels such as TRPV1 and TRPV4 with subsequent vasodilation (Kwan, Huang & Yao, 2007), thus impairing pressure-induced contractile response in RD CFAs while maintaining bradykinin's endothelial response.

The loss of NO release and altered regulation in the endothelium can be exacerbated by chronic high salt and inflammatory insult together, seen in HSD CFAs. The detrimental effect of pro-inflammatory mediators on the endothelial response likely occurs through decrease in regulation of endothelial nitric oxide (eNOS) and endothelial derived hyperpolarizing factor (EDHF; Neumann, Gertzberg & Johnson, 2004)–potentially activated by bradykinin (Félotou & Vanhoutte, 2009), leading to diminished EDHF-initiated relaxation of the vascular smooth muscle (Kessler et al., 1999). The lack of significant difference in L-NAME or bradykinin response between inflamed and non-inflamed RD-fed SHR may be due to a lower TNF-α response seen in the RD CFA rats compared to RD SAL rats (Randell & Daneshtalab, 2016).

A significant degree of vascular smooth muscle dysfunction was also observed, associated with both diet and inflammation. While the HSD CFA group had a significantly diminished response to both vasopressin and phorbol ester (compared to HSD SAL), the RD CFA group only showed a diminished response to PKC activation (compared to RD SAL; Figs. 5D and 5E). The impaired response to PKC activation in both inflamed groups is akin to the decrease in PKC activity previously observed in the post-stroke SHRsp (Smeda, King & Harder, 1999). MCA remodeling due to pro-inflammatory
mediators may account for the dysfunctional response to sarcoplasmic calcium release (vasopressin) as well as PKC activation (phorbol dibutyrate) (Bastin & Heximer, 2011). Also, there is evidence of increasing matrix metalloproteinase activity and increasing proliferation of vascular smooth muscle cells with TNF-α (Lee, Kim & Moon, 2009; Pires et al., 2014). The combined effect of diet and inflammatory insult on V1 receptor (and activation of the PLC/IP3 system) in our HSD CFA group may have led to the failed response to vasopressin as well, while CFA treatment alone may only affect PKC activation via DAG/PKC pathway; PKC, which requires Ca2+ and DAG for activation, has several downstream effects. It is known to interact with MLCK, ERK1/2, Rho kinase and calmodulin-dependent protein kinase II in addition to membrane channels to elicit vascular smooth muscle contraction (Babwah, Dale & Ferguson, 2003; Bastin & Heximer, 2011). Interestingly, the RD CFA group still show pinpoint hemorrhages despite a functioning MCA (Fig. S1) indicating it is still possible to have intracerebral hemorrhage without exhibiting all levels of dysfunction exemplified by the post-stroke SHRsp. The exact signaling alterations associated with the MCA dysfunction remains to be determined.

CONCLUSIONS
Our results indicate that inflammatory injury in the setting of high dietary sodium intake and chronic hypertension leads to a more severe course of inflammatory autoimmune disease. It predisposes the patient to developing an apparently more severe form of HS, organ damage, neuro-inflammation, and loss of cerebrovascular response. The physiological mechanism leading to intracerebral hemorrhage and neural damage is multi-factorial and includes severe hypertension, vascular dysfunction leading to loss of autoregulation of cerebral blood flow, weakening of the BBB leading to cerebral hemorrhage formation (Yamori & Horie, 1977). It is likely that elevated dietary sodium alone is initiating a type of inflammatory process and evidence of cerebral damage. Subsequent inflammatory insult by way of CFA injection inarguably exacerbates this process. The varying levels of neural damage observed in our model, being less severe than what is usually observed in the SHRsp model, allows us to correlate the subsequent tiers of cerebrovascular dysfunction. We believe that patients suffering from RA (and similar systemic inflammatory process) likely experience changes to the cerebral vessels and experience similar neural inflammatory damage, exacerbated by the HSD, as exemplified by our hypertensive-arthritis rat model. Further investigation into the precise mechanisms of neural damage incurred in the RA population suffering from hypertension will promote application of patient-specific treatments to prevent increase in mortality.

LIST OF ABBREVIATIONS
CV Cardiovascular
CFA Complete Freund’s Adjuvant
HS Hemorrhagic stroke
HSD High salt diet
ACKNOWLEDGEMENTS
The authors would like to thank Mr. Marwan Barakji for his contribution to the immunofluorescence staining protocol establishment, Ms. Krista Squires for laboratory management, and experimental monitoring, and the Animal care Facility for providing help with the maintaining the model.

ADDITIONAL INFORMATION AND DECLARATIONS

Funding
The work was funded by RDC/Ignite Grant awarded to Dr. N. Daneshtalab and by Canadian Institutes of Health Research grants (OSO-115895 and MOP-133484) awarded to Dr. Jeffrey G. Dickhout. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Grant Disclosures
The following grant information was disclosed by the authors:
RDC/Ignite.
Canadian Institutes of Health Research: OSO-115895 and MOP-133484.

Competing Interests
The authors declare that they have no competing interests.

Author Contributions
- Amy Randell performed the experiments, analyzed the data, wrote the paper, prepared figures and/or tables, reviewed drafts of the paper.
- Killol Chokshi performed the experiments, analyzed the data, wrote the paper, prepared figures and/or tables, reviewed drafts of the paper.
- Brittany Kane performed the experiments, analyzed the data, reviewed drafts of the paper.
- Hilary Chang performed the experiments, analyzed the data, reviewed drafts of the paper.
Safaa Naiel performed the experiments, analyzed the data, prepared figures and/or tables, reviewed drafts of the paper.

Jeffrey G. Dickhout analyzed the data, contributed reagents/materials/analysis tools, wrote the paper, reviewed drafts of the paper.

Noriko Daneshtalab conceived and designed the experiments, performed the experiments, analyzed the data, contributed reagents/materials/analysis tools, wrote the paper, prepared figures and/or tables, reviewed drafts of the paper.

**Animal Ethics**
The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):

Memorial University Animal Care Committee Approval # 16-30-ND.

**Data Deposition**
The following information was supplied regarding data availability:

The raw data has been supplied as Supplemental Dataset Files.

**Supplemental Information**
Supplemental information for this article can be found online at http://dx.doi.org/10.7717/peerj.2608#supplemental-information.

**REFERENCES**

Babwah AV, Dale LB, Ferguson SSG. 2003. Protein kinase C isoform-specific differences in the spatial-temporal regulation and decoding of metabotropic glutamate receptor1a-stimulated second messenger responses. *Journal of Biological Chemistry* **278**(7):5419–5426 DOI 10.1074/jbc.M211053200.

Bassenge E, Heusch G. 1990. Endothelial and neuro-humoral control of coronary blood flow in health and disease. *Reviews of Physiology, Biochemistry and Pharmacology*. Vol. 116. Berlin, Heidelberg: Springer, 77–165.

Bastin G, Heximer SP. 2011. Intracellular regulation of heterotrimeric G-protein signaling modulates vascular smooth muscle cell contraction. *Archives of Biochemistry and Biophysics* **510**(2):182–189 DOI 10.1016/j.abb.2011.05.008.

Baumbach GL, Faraci FM, Heistad DD. 1994. Effects of local reduction in pressure on endothelium-dependent responses of cerebral arterioles. *Stroke* **25**(7):1456–1461 DOI 10.1161/01.STR.25.7.1456.

Baumbach GL, Hajdu MA. 1993. Mechanics and composition of cerebral arterioles in renal and spontaneously hypertensive rats. *Hypertension* **21**(6 Pt 1):816–826 DOI 10.1161/01.HYP.21.6.816.

Baumbach GL, Heistad DD. 1989. Remodeling of cerebral arterioles in chronic hypertension. *Hypertension* **13**(6 Pt 2):968–972 DOI 10.1161/01.HYP.13.6.968.

Book C, Saxne T, Jacobsson LT. 2005. Prediction of mortality in rheumatoid arthritis based on disease activity markers. *Journal of Rheumatology* **32**(3):430–434.

Brennan FM, Feldmann M. 1992. Cytokines in autoimmunity. *Current Opinion in Immunology* **4**(6):754–759 DOI 10.1016/0952-7915(92)90057-L.
Chauhan A, Sun Y, Pani B, Quenumzangbe F, Sharma J, Singh BB, Mishra BB. 2014. Helminth induced suppression of macrophage activation is correlated with inhibition of calcium channel activity. *PLoS ONE* **9**(7):e101023 DOI 10.1371/journal.pone.0101023.

Croxford AL, Waisman A, Becher B. 2013. Does dietary salt induce autoimmunity? *Cell Research* **23**(7):872–873 DOI 10.1038/cr.2013.65.

Daneshtalab N, Smeda JS. 2010. Alterations in the modulation of cerebrovascular tone and blood flow by nitric oxide synthases in SHRsp with stroke. *Cardiovascular Research* **86**(1):160–168 DOI 10.1093/cvr/cvp395.

Dette S, Saclani Jotti G, Dowssett M. 1995. A “quickscore” method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. *Journal of Clinical Pathology* **48**(9):876–878 DOI 10.1136/jcp.48.9.876.

Donnan GA, Fisher M, Macleod M, Davis SM. 2008. Stroke. *Lancet* **371**(9624):1612–1623 DOI 10.1016/S0140-6736(08)60694-7.

Durand MJ, Raffai G, Weinberg BD, Lombard JH. 2010. Angiotensin-(1–7) and low-dose angiotensin II infusion reverse salt-induced endothelial dysfunction via different mechanisms in rat middle cerebral arteries. *American Journal of Physiology: Heart and Circulatory Physiology* **299**(4):H1024–H1033 DOI 10.1152/ajpheart.00328.2010.

Fedchenko N, Reifenrath J. 2014. Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue—a review. *Diagnostic Pathology* **9**(1):221 DOI 10.1186/s13000-014-0221-9.

Feldmann M, Maini SRN. 2008. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. *Immunological Reviews* **223**(1):7–19 DOI 10.1111/j.1600-065X.2008.00626.x.

Félétou M, Vanhoutte PM. 2009. EDHF: an update. *Clinical Science* **117**(4):139–155 DOI 10.1042/CS20090096.

Feng W, Ying W-Z, Aaron KJ, Sanders PW. 2015. Transforming growth factor-β mediates endothelial dysfunction in rats during high salt intake. *American Journal Physiology: Renal Physiology* **309**(12):F1018–F1025 DOI 10.1152/ajprenal.00328.2015.

Gonzalez A, Kremers HM, Crowson CS, Ballman KV, Roger VL, Jacobsen SJ, O’Fallon WM, Gabriel SE. 2008. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? *Annals of the Rheumatic Diseases* **67**(1):64–69 DOI 10.1136/ard.2006.059980.

Henics T, Wheatley DN. 1999. Cytoplasmic vacuolation, adaptation and cell death: a view on new perspectives and features. *Biology of the Cell* **91**(7):485–498 DOI 10.1016/S0248-4900(00)88205-2.

Henke N, Schmidt-Ullrich R, Dechend R, Park J-K, Qadri F, Wellner M, Obst M, Gross V, Dietz R, Luft FC, Scheidereit C, Muller DN. 2007. Vascular endothelial cell-specific NF-κB suppression attenuates hypertension-induced renal damage. *Circulation Research* **101**(3):268–276 DOI 10.1161/CIRCRESAHA.107.150474.

Izawa-Ishizawa Y, Ishizawa K, Sakurada T, Imanishi M, Miyamoto L, Fujii S, Taira H, Kihira Y, Ikeda Y, Hamano S, Tomita S, Tsuchiya K, Tamaki T. 2012. Angiotensin II receptor blocker improves tumor necrosis factor-α-induced cytotoxicity via antioxidative effect in human glomerular endothelial cells. *Pharmacology* **90**(5–6):324–331 DOI 10.1159/000343244.

Johnson PC. 1986. Autoregulation of blood flow. *Circulation Research* **59**(5):483–495 DOI 10.1161/01.RES.59.5.483.
Kannan, K. Ortmann, RA, Kimpel. 2005. Animal models of rheumatoid arthritis and their relevance to human disease. Pathophysiology 12(3):167–181 DOI 10.1016/j.pathophys.2005.07.011.

Kessler, P., Popp R., Busse R., Schini-Kerth VB. 1999. Proinflammatory mediators chronically downregulate the formation of the endothelium-derived hyperpolarizing factor in arteries via a nitric oxide/cyclic GMP-dependent mechanism. Circulation 99(14):1878–1884 DOI 10.1161/01.CIR.99.14.1878.

Kleinnietfeld M., Manzel A., Titze J., Kvakan H., Yosef N., Linker RA., Muller DN., Hafler DA. 2013. Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells. Nature 496(7446):518–522 DOI 10.1038/nature11868.

Kwan, H-Y., Huang Y., Yao X. 2007. TRP channels in endothelial function and dysfunction. Biochimica et Biophysica Acta (BBA)–Molecular Basis of Disease 1772(8):907–914 DOI 10.1016/j.bbadis.2007.02.013.

Lee, S-J., Kim W-J., Moon S-K. 2009. TNF-α regulates vascular smooth muscle cell responses in genetic hypertension. International Immunopharmacology 9(7–8):837–843 DOI 10.1016/j.intimp.2009.03.010.

Lindhardsen J., Ahlehoff O., Gislason GH., Madsen OR., Olesen JB., Svendsen JH., Torp-Pedersen C., Hansen PR. 2012. Risk of atrial fibrillation and stroke in rheumatoid arthritis: Danish nationwide cohort study. BMJ 344:e1257 DOI 10.1136/bmj.e1257.

Neumann, P., Gertzberg N., Johnson A. 2004. TNF-α induces a decrease in eNOS promoter activity. American Journal of Physiology: Lung Cellular and Molecular Physiology 286(2):L452–L459 DOI 10.1152/ajplung.00378.2002.

Numata T., Takahashi K., Inoue R. 2015. “TRP inflammation” relationship in cardiovascular system. Seminars in Immunopathology 38(3):339–356 DOI 10.1007/s00281-015-0536-y.

Pires, PW., Girgla SS., Moreno G., McClain JL., Dorrance AM. 2014. Tumor necrosis factor-α inhibition attenuates middle cerebral artery remodeling but increases cerebral ischemic damage in hypertensive rats. American Journal of Physiology: Heart and Circulatory Physiology 307(5):H658–H669 DOI 10.1152/ajpheart.00018.2014.

Randell A., Daneshtalab N. 2016. Adjuvant-induced mono-arthritis potentiates cerebral hemorrhage in the spontaneously hypertensive rats. Life Sciences 151:15–22 DOI 10.1016/j.lfs.2016.02.012.

Saklatvala J. 1986. Tumour necrosis factor α stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 322(6079):547–549 DOI 10.1038/322547a0.

Shackelford C., Long G., Wolf J., Okerberg C., Herbert R. 2002. Qualitative and quantitative analysis of nonneoplastic lesions in toxicology studies. Toxicologic Pathology 30(1):93–96 DOI 10.1080/01926230252824761.

Smeda J. 1992. Cerebrovascular changes associated with hemorrhagic stroke in hypertension. Canadian Journal of Physiology and Pharmacology 70(4):552–564 DOI 10.1139/y92-070.

Smeda J., Daneshtalab N. 2011. The effects of poststroke captopril and losartan treatment on cerebral blood flow autoregulation in SHRsp with hemorrhagic stroke. Journal of Cerebral Blood Flow & Metabolism 31(2):476–485 DOI 10.1038/jcbfm.2010.110.

Smeda J., King S. 2000. Electromechanical alterations in the cerebrovasculature of stroke-prone rats. Stroke 31(3):751–759 DOI 10.1161/01.STR.31.3.751.

Sokka T., Abelson B., Pincus T. 2008. Mortality in rheumatoid arthritis: 2008 update. Clinical and Experimental Rheumatology 26(3 Suppl 51):S35–S61.
Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, Stampfer MJ, Curhan GC. 2003. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. *Circulation* **107**(9):1303–1307 DOI 10.1161/01.CIR.0000054612.26458.B2.

Sprague AH, Khalil RA. 2009. Inflammatory cytokines in vascular dysfunction and vascular disease. *Biochemical Pharmacology* **78**(6):539–552 DOI 10.1016/j.bcp.2009.04.029.

Sutherland GR, Auer RN. 2006. Primary intracerebral hemorrhage. *Journal of Clinical Neuroscience* **13**(5):511–517 DOI 10.1016/j.jocn.2004.12.012.

Thrift AG, McNeil JJ, Forbes A, Donnan GA. 1996. Risk factors for cerebral hemorrhage in the era of well-controlled hypertension. Melbourne Risk Factor Study (MERFS) Group. *Stroke* **27**(11):2020–2025 DOI 10.1161/01.STR.27.11.2020.

Vanhoutte PM, Mombouli J-V. 1996. Vascular endothelium: vasoactive mediators. *Progress in Cardiovascular Diseases* **39**(3):229–238 DOI 10.1016/S0033-0620(96)80003-X.

Yamori Y. 1984. The development of Spontaneously Hypertensive Rat (SHR) and of various spontaneous rat models, and their implications. In: de Jong W, ed. *Handbook of Hypertension*. Vol. 4. Experimental and Genetic Models of Hypertension. Vol. 4. Amsterdam: Elsevier, 224–239.

Yamori Y, Horie R. 1977. Developmental course of hypertension and regional cerebral blood flow in stroke-prone spontaneously hypertensive rats. *Stroke* **8**(4):456–461 DOI 10.1116/01.STR.8.4.456.

Zöller B, Li X, Sundquist J, Sundquist K. 2012. Risk of subsequent ischemic and hemorrhagic stroke in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden. *BMC Neurology* **12**(1):41 DOI 10.1186/1471-2377-12-41.